Skip to content Skip to footer
Subscribe Now

NEWS

FibroGen & AstraZeneca
AstraZeneca Purchases FibroGen China for ~$160M
Shots: AstraZeneca has purchased FibroGen’s China subsidiary for ~$160M ($85M enterprise value + ~$75M net cash) with closing expected in mid-2025, obtaining full rights to roxadustat in China The sale allows FibroGen to repay its Morgan Stanley Tactical Value loan & extend its cash runway to 2027 for advancing FG-3246 in P-II trial for…
February 21, 2025
Akesobio
Akeso Reports First Patient Enrollment in P-III Study of Ivonescimab + CT to Treat Triple-Negative Breast Cancer (TNBC) in China
Shots: Akeso enrolled the first patient in the P-III (HARMONi-BC1/AK112-308)  study of Ivonescimab + CT  for the treatment of unresectable locally advanced or metastatic TNBC (already approved for EGFR-TKI-resistant, non-squamous NSCLC in China) The preliminary efficacy data presented at ESMO’24 showed significant therapeutic efficacy of ivonescimab + CT and a favorable safety profile for…
February 21, 2025
 Mayne Pharma
Cosette Pharmaceuticals to Acquire Mayne Pharma for ~$430M
Shots: Cosette Pharmaceuticals to acquire Mayne Pharma Group for ~$430M, with shareholders receiving $4.71/share. Closing expected in Q2’25 Acquisition will strengthen Cosette’s dermatology & women’s health business, adding 12 patent-protected products incl. Vyleesi, Intrarosa, Nextstellis, Annovera, Bijuva, Imvexxy, & Rhofade along with multiple pipeline candidates in its product line upon closing The combined…
February 21, 2025
Incyte & Genesis Therapeutics
Elanco Launches Pet Protect Supplement Line for Dogs and Cats
Shots: Elanco has introduced Pet Protect, a veterinarian-formulated supplement line with scientifically-backed ingredients & NASC quality seal for dogs & cats designed to target their various health needs Pet Protect line incl. supplements like Synovi G3 formula (hip & joint support), DVM Daily Soft Chews (multivitamins) & Lactoquil (digestive health) to maintain GI health…
February 21, 2025
Harbour BioMed &  Insilico Medicine
Harbour BioMed Enters into a Collaboration with Insilico Medicine to Advance AI-Driven Antibody Discovery and Development
Shots: Harbour BioMed has entered into a strategic collaboration with Insilico Medicine to accelerate therapeutic antibody development, combining their expertise in antibody discovery and artificial intelligence The companies will also collaborate on early-stage drug discovery targeting novel antibodies, leveraging Insilico's AI expertise and Harbour BioMed's wet lab capabilities for immunology, oncology, and neuroscience, aiming…
February 20, 2025
Load more